Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Omelianenko, A. Makarevich, E. Anmelchenko, T. Rybina (Minsk, Belarus). Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP). Eur Respir J 2010; 36: Suppl. 54, 2211

Member's Comments

No comment yet.

Related content which might interest you: The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Community-acquired pneumonia in COPD patients: GOLD staging is a strong predicting factor of outcome of pneumonia Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010 Biomarkers and community-adquired pneumonia (CAP) etiology Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Copeptin application in severe community-acquired pneumonia (SCAP) severity assessment and outcomes Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Prognostic factors of mortality in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 239s Year: 2003 Community-acquired pneumonia (CAP): evaluation of severity criteria for hospitalization Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003 Biomarkers and clinical stability in community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 The role of procalcitonin in predicting severity and clinical course of aspiration pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Prognostic evaluation of COPD patients with pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 257s Year: 2005 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Validation of indices and predictive rules of severity for community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 560s Year: 2002 Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Validation of a predictive rule for the management of community-acquired pneumonia Source: Eur Respir J 2006; 27: 151-157 Year: 2006 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016